Switch theme
Sign up to access all valuation multiples
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
2004
170
LTM Revenue $24.0M
Last FY EBITDA -$116M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Liquidia has a last 12-month revenue (LTM) of $24.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Liquidia achieved revenue of $14.0M and an EBITDA of -$116M.
Liquidia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Liquidia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.0M | XXX | $14.0M | XXX | XXX | XXX |
| Gross Profit | $17.1M | XXX | $8.1M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$116M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -827% | XXX | XXX | XXX |
| EBIT | -$125M | XXX | -$121M | XXX | XXX | XXX |
| EBIT Margin | -520% | XXX | -867% | XXX | XXX | XXX |
| Net Profit | -$133M | XXX | -$130M | XXX | XXX | XXX |
| Net Margin | -556% | XXX | -932% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Liquidia's stock price is $15.
Liquidia has current market cap of $1.3B, and EV of $1.3B.
See Liquidia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | $-1.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Liquidia has market cap of $1.3B and EV of $1.3B.
Liquidia's trades at 89.5x EV/Revenue multiple, and -10.8x EV/EBITDA.
Equity research analysts estimate Liquidia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Liquidia has a P/E ratio of -9.6x.
See valuation multiples for Liquidia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 52.3x | XXX | 89.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.8x | XXX | XXX | XXX |
| EV/EBIT | -10.1x | XXX | -10.3x | XXX | XXX | XXX |
| EV/Gross Profit | 73.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.6x | XXX | -9.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLiquidia's last 12 month revenue growth is 342%
Liquidia's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.
Liquidia's rule of 40 is -58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Liquidia's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Liquidia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 342% | XXX | 280% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -827% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -58% | XXX | -484% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 342% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 925% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Liquidia acquired XXX companies to date.
Last acquisition by Liquidia was XXXXXXXX, XXXXX XXXXX XXXXXX . Liquidia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Liquidia founded? | Liquidia was founded in 2004. |
| Where is Liquidia headquartered? | Liquidia is headquartered in United States of America. |
| How many employees does Liquidia have? | As of today, Liquidia has 170 employees. |
| Who is the CEO of Liquidia? | Liquidia's CEO is Dr. Roger A. Jeffs, PhD. |
| Is Liquidia publicy listed? | Yes, Liquidia is a public company listed on NAS. |
| What is the stock symbol of Liquidia? | Liquidia trades under LQDA ticker. |
| When did Liquidia go public? | Liquidia went public in 2018. |
| Who are competitors of Liquidia? | Similar companies to Liquidia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Liquidia? | Liquidia's current market cap is $1.3B |
| What is the current revenue of Liquidia? | Liquidia's last 12 months revenue is $24.0M. |
| What is the current revenue growth of Liquidia? | Liquidia revenue growth (NTM/LTM) is 342%. |
| What is the current EV/Revenue multiple of Liquidia? | Current revenue multiple of Liquidia is 52.3x. |
| Is Liquidia profitable? | Yes, Liquidia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
